asthma, obesity
Conditions
Interventions
no intervention
Sponsors
Leiden University Medical Center
Eligibility
Inclusion criteria
Inclusion criteria: • Age ≥ 18 who have signed informed consent form prior to the start of the study • Clinical diagnosis for ≥ 6 months of asthma • Stable asthma: on a stable dose of asthma inhalation medication for at least 8 weeks prior to baseline visit • Obese (BMI >30) or non-obese (BMI <30) Asthma was defined according to the Global Initiative for Asthma 2015 guidelines as: - presence of symptoms and - an increase of ≥12% and 200mL in FEV1 after salbutamol or - a positive provocation test (methacholine PC20 <8 - 16mg/ml)
Exclusion criteria
Exclusion criteria: • Change of asthma inhalation medication in the past 8 weeks before visit 1 • Asthma exacerbation (defined as use of oral or intravenous corticosteroids and/or antibiotics) in the past 8 weeks before visit 1 • Smokers: current ≥ 10 cigarettes per day or ≥10 pack years • Diagnosis of COPD • Pregnancy, as reported by the participant • Clinical or functional uncontrolled respiratory- or other disease that might, in the judgement of the investigator, comprise the results or interpretation of the study • Current- or less than 1 month from baseline participation in interventional clinical trial with inhalation drugs • Inability to comply with study procedures
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| - other measurements of small airway function - blood eosinophil count and total IgE - sputum eosinophil count - asthma control questionnaire - mini asthma quality of life questionnaire - bronchial hyper-responsiveness questionnaire - 8-item morisky medication adherence scale | — |
Primary
| Measure | Time frame |
|---|---|
| impulse oscillometry | — |
Contacts
Public ContactT.N. Bonten
Outcome results
None listed